Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer


Series A | Alive

About Drug Response Dx

Drug Response Dx is developing a biomarker test kit for rheumatoid arthritis treatment guidance with so-called TNF-alpha inhibitors. The test is secured by a unique patent platform exclusively in-licensed by the Max Planck Society.

Drug Response Dx Headquarter Location


+49 (0) 3302 55199 85

Latest Drug Response Dx News

Drug Response Dx Closes First Round of Financing

Jan 8, 2013

By FinSMEs Drug Response Dx , a Hennigsdorf, Germany-based developer of proprietary RA biomarkers based on technology licensed from Max-Planck-Innovation , closed itd first round of financing. Founded in February 2012 by Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner and Dr. Joachim Rautter, Drug Response Dx aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients. The company intends to use the capital, whose amount was not disclosed, to advance its biomarker test kit for rheumatoid arthritis treatment. A proof of concept is already in place for the antibody-based verification procedure in an ELISA format (Enzyme Linked Immunosorbent Assay). The required biomarkers can also already be produced in high technical quality and fairly large quantities. FinSMEs

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.